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Abstract
Introduction: Epidemiological studies have highlighted a negative association between diabetes and abdominal aortic aneurysm (AAA). The aim 
of this study was to investigate the association between insulin resistance and AAA size. 
Materials and methods: This prospective cross sectional monocentric study analysed fasting blood samples from 55 patients with AAA eligible 
for surgical repair. They were divided into 2 groups according to the median AAA diameter:  diameter < 50 mm (N = 28) and diameter > 50 mm (N 
= 27). The median ages were respectively 73 years (62 - 79) and 72 years (67 - 81). Glucose and fructosamine concentrations were determined by 
spectrophotometry; insulin and C-peptide using chemiluminescent technology. Homeostasis model assessment 2 calculator was used to estimate 
insulin resistance index (HOMA2 IR).
Results: There was no significant difference for fasting glucose concentration between the groups (6.1 vs. 5.9 mmol/L, P = 0.825). C-peptide and 
insulin concentrations, as well as HOMA2 IR index were significantly higher in patients with AAA > 50 mm (0.82 vs. 0.54 nmol/L, P = 0.012; 9 vs. 5 
mU/L, P = 0.019 and 1.72 vs. 1.26, P = 0.028, respectively). No linear correlation was identified between AAA diameter and HOMA2 IR. Fructosamine 
concentration was lower in patients with AAA > 50 mm (225.5 vs. 251 μmol/L, P = 0.005) and negatively correlated with AAA diameter (r = - 0.54, 
P < 0.001). 
Conclusion: This study evidenced an association between AAA diameter and insulin resistance. Further studies are required to determine a causal 
link between insulin resistance and AAA development.
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Abdominal aortic aneurysm (AAA), generally defi-
ned as a focal dilatation of the aorta superior to 30 
mm in diameter, represents a life-threatening dise-
ase (1). It is estimated to be the tenth commonest 
cause of mortality, as a result of severe complicati-
ons such as aortic rupture (2). Despite advances in 
the management of patients, specific pharmacolo-
gical approaches to treat and limit aneurysm 
expansion are still lacking and the only curative 
therapeutic option relies on surgical interventions 
including open and endovascular surgery (1,2). 
The decision to treat patients relies on the balance 
between the operative risks and the risks of pro-
gression and rupture. Symptomatic aneurysms, 
which are often manifested by abdominal or back 
pain, or rupture, should be promptly treated (1). 
For asymptomatic patients, there is general agree-
ment that small aneurysms (< 40 mm in diameter) 
and at low risk of rupture should be monitored, 
whereas bigger aneurysms (> 54 mm) or at high 
risk of rupture should be repaired (1). 
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Abdominal aortic aneurysm is most often associa-
ted with atherosclerosis and corresponding cardi-
ovascular risk factors including age, male sex, smo-
king, arterial hypertension and dyslipidaemia (3,4). 
Abdominal aortic aneurysm formation results 
from a complex process involving mainly extra-
cellular matrix (ECM) remodelling, infiltration of in-
flammatory cells within the aortic wall as well as 
impairment of vascular smooth muscle cell home-
ostasis and increased oxidative stress (3). Intriguin-
gly, while diabetes mellitus represents a major car-
diovascular risk factor, epidemiological studies 
have pointed out a negative association between 
diabetes and AAA (5-12). Both prevalence and inci-
dence of AAA were found to be lower in diabetic 
patients compared to non-diabetics (6-10,13). In 
addition, several reports have shown that diabetic 
patients develop smaller aneurysm and have 
lower growth rates of AAA (6,8,13-17). At last, a ne-
gative association was found between diabetes 
and AAA rupture (18). These results suggest a pro-
tective effect of diabetes on AAA formation and 
the understanding of the mechanisms involved 
could bring innovative therapeutic strategies for 
the patients. 
The pathophysiological mechanisms underlying 
the protective effect of diabetes on AAA occurren-
ce and development are not totally understood 
and may be multifactorial through effects on ECM 
remodelling, inflammation, vascular smooth 
muscle cell homeostasis, neoangiogenesis, and 
thrombus formation (6,19). In addition, the use of 
antidiabetic drugs has also been paradoxically 
identified as a protective factor against AAA for-
mation (20,21).
Type 2 diabetes, which accounts for 90% of diabe-
tic patients, is characterized by a chronic hyper-
glycaemia resulting from insulin resistance asso-
ciated with defects in insulin secretion. Several 
studies have previously addressed the link betwe-
en hyperglycaemia on AAA development. An in-
verse correlation was found between fasting blo-
od glucose and glycated haemoglobin A1c (reflec-
ting long-term glucose concentrations) with AAA 
diameter (14,16). While the link between blood 
glucose concentration and AAA development is 
well described, the association between AAA and 
insulin resistance has never been explored. We 
previously published a pilot study which compa-
red plasma inflammatory profile between diabetic 
and non-diabetic patients with AAA (19). However, 
we did not address the association between insu-
lin resistance and AAA independently of diabetic 
status. Insulin resistance impairs vascular function 
and play roles in mechanisms potentially relevant 
for AAA pathogenesis. Insulin resistance is associa-
ted with increased oxidative stress and inflamma-
tion and can impact on vascular smooth muscle 
cells survival (22-25). We hypothesized that unlike 
chronic hyperglycaemia, insulin resistance may be 
positively associated with AAA development. Ba-
sed on our previously published cohort, the aim of 
this study was to investigate the association 
between insulin resistance and AAA size.
Material and methods
Study design and subjects
This prospective monocentric cross-sectional stu-
dy included patients with AAA eligible to surgical 
repair in the Department of Vascular Surgery at 
the University Hospital of Nice from January 2016 
to February 2017. This study involves a previously 
published clinical cohort (19). It was conducted in 
conformity with the Declaration of Helsinki and 
was approved by our institutional local ethics 
committee (Comité de Protection des Personnes 
Sud Méditerranée V). All enrolled patients gave in-
formed written consent. 
Inclusion criteria were patients over 18 years with 
AAA eligible to aortic surgical repair. The diagnosis 
of AAA was defined as a focal dilatation of the ab-
dominal aorta with a diameter superior to 30 mm, 
in accordance with the current guidelines of vas-
cular surgery (1). Abdominal aortic aneurysm dia-
meter was measured on injected CT-scan by trai-
ned vascular surgeons. Eligibility to aortic surgical 
repair was discussed by a multidisciplinary team 
composed of vascular surgeons and anaesthetists 
based on the balance between the operative risk 
and the risk of progression and rupture (1). The ae-
tiologies of AAA were evaluated based on patient’s 
history, clinical presentation, results of biological 
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and imaging investigations. Patients who had a 
declared history of systemic inflammatory disease 
(connective tissue disease or vasculitis) or a gene-
tic disorder potentially leading to AAA (Marfan, 
Ehlers Danlos or Loeys Dietz syndrome) were 
excluded. Patients who had a mycotic aneurysm 
were excluded based on the results of biological 
and imaging investigations. 
At the time of inclusion, clinical pre-operative cha-
racteristics were collected including age, sex, the 
presence of diabetes, arterial hypertension, dysli-
pidaemia and smoking habits, based on patient’s 
declaration, medical records and treatments. The 
height and the weight were measured and the 
body mass index was calculated by dividing the 
weight (kg) by the square of the body height (m2). 
The patient treatments were recorded based on 
medical prescriptions. Data were collected using 
electronic or manuscript medical records, as well 
as by a computer software program named Clini-
com® (InterSystems Corporation, Cambridge, USA). 
Imaging data were recorded and extracted from 
the Picture Archiving and Communication System 
(PACS®) multiple modalities software. Post-proce-
ssing analysis was performed using the Aquarius® 
workstation (TeraRecon Inc., San Mateo, USA).
In total, 55 patients were included. To investigate 
the link between glycaemic parameters, insulin re-
sistance and AAA size, the study population was 
divided into 2 subgroups (N = 28 and N = 27, res-
pectively) based on the median value of the AAA 
diameter. The median value of AAA diameter was 
50 mm (interquartile range: 46 - 56). Patients with 
AAA < 50 mm had a median age of 73 years (62 - 
79) and patients with AAA > 50 mm had a median 
age of 72 years (67 - 81). 
Blood sampling
Blood samples were obtained after a peripheral 
vein puncture from the antecubital vein after 8 to 
12 hours fasting the day before the surgical inter-
vention. Blood was collected into 5 mL BD Vacuta-
iner® tubes (Becton Dickinson and Company, Le 
Pont de Claix, France). Blood was collected in two 
different vacutainer tubes. Tube with serum sepa-
rator and clot activator for determination of insu-
lin, C-peptide and fructosamine was used, and for 
plasma glucose measurement tube coated with 
sodium fluoride was used. Blood was collected in 
the Department of Vascular Surgery and immedia-
tely sent to the Department of Clinical Biochemi-
stry. Samples were centrifuged at 20 °C for 10 mi-
nutes at 3000xg within 2 hours after collection 
and sera were immediately analysed. Two aliquots 
of remaining sera (200 µL each) were then stored 
at - 80 °C for back-up. 
Methods
All the analyses were performed in the Clinical 
Chemistry Laboratory at the University Hospital of 
Nice using standard methods. All the analyses 
were certified by the National French Committee 
of Accreditation. Calibration was done before qua-
lity controls according to the manufacturer’s in-
structions. For all assays, quality controls fell wit-
hin limits defined by the manufacturer and current 
guidelines (26,27). Glucose and fructosamine con-
centrations were determined by spectrophotome-
try (Cobas 8000, Roche Diagnostics, Meylan, Fran-
ce). Calibrators and controls were obtained from 
Roche (Roche Diagnostics, Meylan, France); blank 
and Calibrator for Automated Systems (10.8 
mmol/L) for determination of glucose; blank and 
Precimat Fructosamine (400 µmol/L) for the mea-
sure of fructosamine. For glucose determination, 
two quality controls were used: Precicontrol 
ClinChem Multi 1 (5.6 mmol/L) and Precicontrol 
ClinChem Multi 2 (13.4 mmol/L). The inter-assay 
coefficients of variation (CVs) were 1.03% and 
1.12%, respectively. For fructosamine determinati-
on controls used were: Precinorm Fructosamine 
(280 µmol/L) and Precipath Fructosamine (540 
µmol/L). The inter-assay CVs were 1.9% and 1.6%, 
respectively.
Insulin and C-peptide were measured with a 
sandwich immunoassay using direct chemilumi-
nescent technology (Centaur XP, Siemens Healt-
hineers GmbH, Erlangen, Germany). Calibrators 
were obtained from Siemens Healthineers. For in-
sulin determination, three quality controls from Bi-
orad Clinical Diagnostics (Marnes-la-Coquette, 
France) were used: Liquichek Immunoassay Plus 
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Quality Control (19, 78 and 192 mU/L). The inter-
assay CVs were 5.0, 4.8 and 5.2%, respectively. For 
C-peptide determination, three quality controls 
from Biorad Clinical Diagnostics (Marnes-la-Coqu-
ette, France) were used: Liquichek Specialty Qua-
lity Control (0.416, 1.630 and 4.650 nmol/L). The in-
ter-assay CVs were 4.4, 5.3 and 4.6%, respectively.
Fasting glucose concentrations were interpreted 
according to the criteria defined by the American 
Diabetes Association (28). Diabetes was defined as 
fasting glucose concentration > 7.0 mmol/L. Impa-
ired fasting glucose concentration corresponded 
to glucose concentration between 5.6 and 6.9 
mmol/L.
Homeostasis model assessment 2 (HOMA2) calcu-
lator was used to estimate steady state beta cell 
function (HOMA 2 %B), insulin sensitivity (HOMA2 
%S) and insulin resistance index (HOMA2 IR) from 
fasting glucose and C-peptide concentration (29). 
As stated by the “Diabetes Trials Unit from the 
Oxford Centre for Diabetes”, no absolute defined 
threshold for normal ranges for HOMA values exist 
and HOMA indices were directly compared betwe-
en the two study groups. 
Statistical analysis
Categorical data were expressed as the number of 
patients and ratios, and continuous variables were 
expressed as the median with interquartile ranges. 
Given the low number of patients, group differen-
ces were compared using non-parametric Mann-
Whitney test. Fisher’s exact test was used for cate-
gorical data. Correlations were determined by 
non-parametric Spearman’s correlation coeffici-
ent. A P value < 0.05 was considered as significant. 
Statistical analyses were performed using 
GraphPad Prism® software (version 7.00, La Jolla 
California USA).
Results 
The general characteristics of patients enrolled in 
the study are presented in Table 1. No significant 
difference was observed for the sex ratio between 
patients with AAA < 50 mm and those with AAA > 
50 mm (male: 25/28 and 23/27, P = 0.705). The me-
dian body mass index did not significantly differ 
(24.5 vs 24.5, P = 0.145). There was no significant 
difference regarding the proportion of patients 
with arterial hypertension, dyslipidaemia or smo-
king habits between the 2 groups. No difference 
was observed regarding the treatments including 
the use of statins, antiplatelets, antihypertensives 
or oral anti-diabetic drugs between the 2 groups. 
Fasting glucose concentration did not significantly 
differ between the 2 groups (6.1 vs 5.9 mmol/L, P = 
0.825). There was no significant difference regar-
ding the proportion of patients with a declared hi-
story of type 2 diabetes between the 2 groups 
(6/28 vs 5/27, P = 0.999). When analysing fasting 
glucose concentration, further 5/28 patients with 
AAA < 50 mm and 6/27 patients with AAA > 50 
mm had a glucose concentration > 7 mmol/L, 
which defines diabetic state, but were unaware of 
their diagnosis. Eight out of 28 patients with AAA 
< 50 mm and 7/27 patients with AAA > 50 mm had 
a glucose concentration between 5.6 and 6 
mmol/L, which corresponds to impaired fasting 
glucose concentration defining prediabetic state.
C-peptide and insulin concentrations were signifi-
cantly higher in patients with AAA > 50 mm com-
pared to those with AAA < 50mm (0.82 vs 0.54 
nmol/L, P = 0.012 and 9 vs 5 mU/L, P = 0.019, res-
pectively). Insulin resistance index was also signifi-
cantly higher in patients with AAA > 50 mm 
(HOMA2 IR: 1.72 vs 1.26, P = 0.028). There was no 
significant difference for the steady state beta cell 
function (HOMA2 %B) between the 2 groups (97.3 
vs 68.3%, P = 0.491). Fructosamine concentration 
was significantly lower in patients with AAA > 50 
mm (225.5 vs 251 μmol/L, P = 0.005). 
We further investigated the potential correlation 
between glycaemic parameters and AAA size (Ta-
ble 2). In our study, glucose, C-peptide, insulin con-
centrations and insulin resistance (HOMA IR) did 
not directly correlate with AAA diameter, as revea-
led by Pearson’s correlation coefficient closed to 
zero. However, fructosamine concentration nega-
tively correlated with AAA size (r = - 0.54, P < 
0.001). 
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Glycaemic parameters r P 
Fasting glucose (mmol/L) 0.04 0.797
C-peptide (nmol/L) 0.15 0.327
Insulin (mU/L) 0.13 0.385
Fructosamine (μmol/L) - 0.54 < 0.001
HOMA2 %B - 0.06 0.665
HOMA2 %S - 0.09 0.544
HOMA2 IR 0.09 0.538
r - Spearman’s correlation coefficient. HOMA2 %B - steady 
state beta cell function estimated according to HOMA2 
calculator. HOMA2 %S - insulin sensitivity estimated according 
to HOMA2 calculator. HOMA2 IR - insulin resistance estimated 










Age (years) 73 (62 - 79) 72 (67 - 81) 0.363
Male sex, N (proportion) 25 (0.89) 23 (0.85) 0.705
BMI (kg/m2) 24.5 (26.9 - 30.5) 24.6 (30 - 34.5) 0.145
Type 2 diabetes, N (proportion) 6 (0.21) 5 (0.19) 0.999
Arterial hypertension, N (proportion) 16 (0.57) 18 (0.67) 0.582
Dyslipidaemia, N (proportion) 11 (0.39) 5 (0.19) 0.138
Smoking, N (proportion) 21 (0.75) 20 (0.74) 0.999
Use of statins, N (proportion) 18 (0.64) 14 (0.52) 0.418
Use of antiplatelets, N (proportion) 19 (0.68) 21 (0.78) 0.547
Use of antihypertensive, N (proportion) 15 (0.54) 19 (0.70) 0.270
Use of oral anti-diabetics, N (proportion) 6 (0.21) 5 (0.19) 0.999
AAA diameter (mm) 47 (37 - 50) 56 (53 - 67) < 0.001
Fasting glucose (mmol/L) 5.9 (4.8 - 7.2) 6.1 (5 - 7.5) 0.825
C-peptide (nmol/L) 0.54 (0.38 - 1.02) 0.82 (0.68 - 1.13) 0.012
Insulin (mU/L) 5 (3 - 8) 9 (5 - 13) 0.019
Fructosamine (μmol/L) 251 (225 - 275) 226 (212 - 247) 0.005
HOMA2 %B 68 (49 - 136) 97 (55 - 137) 0.491
HOMA2 %S 79 (47 - 115) 58 (36 - 70) 0.029
HOMA2 IR 1.3 (0.9 - 2.1) 1.7 (1.4 - 2.8) 0.028
AAA - abdominal aortic aneurysm. BMI - body mass index. HOMA2 %B - steady state beta cell function estimated according to 
HOMA2 calculator. HOMA2 %S - insulin sensitivity estimated according to HOMA2 calculator. HOMA2 IR - insulin resistance 
estimated according to HOMA2 calculator. Values are median (interquartile range) or N (proportion). P value < 0.05 was considered 
as significant.
Table 1. Characteristics of patients enrolled in the study
Table 2. Correlation analyses between glycaemic parameters 
and AAA diameter
Discussion
Most of the studies published so far compared fea-
tures between diabetic and non-diabetic patients 
with AAA (19, 30-34). To the best of our knowled-
ge, this is the first study addressing the association 
between insulin resistance and AAA. We found 
that patients with AAA > 50 mm had significantly 
higher C-peptide and insulin concentrations com-
pared to patients with AAA < 50 mm, despite no 
difference in fasting blood glucose. These results 
are in accordance with a previous published study 
reporting a positive correlation between C-pepti-
de concentration and AAA diameter (35). In additi-
on, we found that patients with AAA > 50 mm had 
significantly higher insulin resistance index as esti-
Biochem Med (Zagreb) 2018;28(3):030702  https://doi.org/10.11613/BM.2018.030702 
6
Lareyre F. et al. Insulin resistance and abdominal aortic aneurysm
mated by HOMA2 calculator, which evidenced an 
association between AAA diameter and insulin re-
sistance index. However, no direct correlation was 
found between AAA diameter and HOMA2 IR, su-
ggesting that the link between both factors may 
be more complex than previously anticipated. The 
HOMA2 model estimates insulin resistance accor-
ding to fasting glucose concentration and insulin 
or C-peptide concentrations and takes into acco-
unt variations in hepatic and peripheral glucose 
resistance. There is currently no absolute establis-
hed threshold to define normal ranges for HOMA 
values as it depends on the specific assays used for 
glucose, insulin and C-peptide measures as well as 
subject ethnicity and gender (29,36,37). Hence, it 
would be worth further to confirm the association 
between insulin resistance and AAA size using 
other established and innovative biomarkers of in-
sulin resistance (38). 
While this study evidenced an association betwe-
en AAA diameter and insulin resistance index, it 
cannot be given any conclusion whether this asso-
ciation is protective or not against AAA formation. 
However, clinical and fundamental research per-
formed so far suggest that insulin resistance may 
favour AAA initiation and progression. Epidemio-
logical studies revealed that the use of insulin sen-
sitizers including biguanides (metformin) and thia-
zolidinediones (rosiglitazone, pioglitazone) was 
associated with a lower risk of developing aneu-
rysm (20). To go further in the cellular pathways in-
volved, experimental studies have been perfor-
med in chemically induced aneurysm animal mo-
dels (39,40). Elastase model requires the applicati-
on or the perfusion of pancreatic porcine elastase 
on the infrarenal abdominal aorta in C57Bl6j mice 
and leads to AAA formation within 14 days. The 
angiotensin II model relies on a continuous 
subcutaneous angiotensin II infusion in C57Bl6j or 
apoE-/- mice inducing AAA usually located in the 
suprarenal aorta within 28 days. Interestingly, the 
administration of metformin reduced the deve-
lopment of elastase-induced AAA, an effect asso-
ciated with a preservation of vascular smooth 
muscle cells and aortic medial elastin and a decre-
ased inflammatory cell infiltration (41). 
Similarly, administration of thiazolidinediones to 
apoE-/- mice perfused with angiotensin II reduced 
aortic dilatation as well as macrophage infiltration 
in aneurysmal tissues (42). 
The link between glycaemic parameters and AAA 
development has been addressed by several stu-
dies. Some investigators identified an inverse 
correlation between AAA diameter and fasting 
blood glucose concentration (14). In our study, we 
did not reproduce this result. This could be, at le-
ast, partly explained by the small size of our co-
hort, which may have limited the statistical power 
of the analysis. Besides, blood glucose concentrati-
on is highly variable throughout the day and does 
not reflect long-term glucose homeostasis (28). By 
contrast, fructosamine has the advantage to re-
flect the average glycaemic status over the prece-
ding 2 to 3-week period and its measurement is 
quick, cheap and fairly free of analytic interferen-
ces (43). Interestingly, a negative correlation 
between fructosamine concentrations and AAA 
diameter was observed, as revealed by a 
Spearman’s coefficient correlation of - 0.54, P < 
0.001. To the best of our knowledge, this is the first 
report that investigated the link between fructosa-
mine and AAA. Other studies have explored the 
association between HbA1c, which reflects the 
glycaemic status over the past 3 months, and iden-
tified an inverse association between the growth 
rate of AAA and the level of HbA1c (16,28). Taken 
together, these results underline the negative 
association between long-term high plasma 
glucose concentrations and AAA diameter. 
At last, we measured fasting glucose concentrati-
on. Even though the aim of this study was not to 
determine diabetic states, we found that some pa-
tients who did not have a declared history of dia-
betes had impaired fasting glucose concentration 
or glycaemia > 7 mmol/L. These results suggest 
that many patients are unaware that they are dia-
betic or pre-diabetic and point to an underestima-
tion of diabetes in patients with AAA. This is in 
accordance with another study which found that 
almost half of patients with AAA were unaware 
that they were diabetics according to HbA1c and 
glucose concentration obtained after an oral 
glucose tolerance test (44). These findings underli-
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ne the real need in practice to improve the detec-
tion of diabetes in patients with AAA. 
This study presents some limitations. First, this was 
a single-centre study involving a small number of 
patients. This could have potentially limited the 
statistical power of the analyses. Second, even if 
the Homeostasis Modell Assessment is a well- 
established tool to evaluate insulin resistance, 
absolute established threshold to define normal 
ranges are lacking (28). The normal reference ran-
ges for HOMA-IR, HOMA %B and HOMA %S are 
impacted by ethnic group and needs to be deter-
mined for every community (30,31). The determi-
nation of normal ranges specifically adapted to 
our cohort would have required to determine in-
sulin resistance indices in a test group and to com-
pare it with analytes reflecting insulin resistance 
symptoms and pathology. This study was not desi-
gned to address it, which represents a limitation. 
Nevertheless, this study allowed a relative compa-
rison of insulin resistance indices between pati-
ents with AAA > 50 mm and those with AAA < 50 
mm. It would be worth to extend this work on lar-
ger cohorts and to use combined biomarkers of in-
sulin resistance to precisely characterize its seve-
rity and its association with AAA. 
This study is of interest as to the best of our 
knowledge, this is the first to investigate the asso-
ciation between AAA size and insulin resistance. 
This may serve as a basis to perform clinical studi-
es on larger cohorts as well as experimental rese-
arches on animal models to explore the molecular 
and cellular pathways relaying the effect of insulin 
resistance on AAA formation. At long term, this co-
uld lead to develop new therapeutic strategies for 
patients with AAA.
In conclusion, to the best of our knowledge, this is 
the first clinical study addressing the association 
between insulin resistance and AAA size. This stu-
dy evidenced an association between AAA diame-
ter and insulin resistance index. However, insulin 
resistance did not directly correlate with AAA dia-
meter, pointing to a complex association between 
these two factors. Further clinical and fundamen-
tal studies are required to establish a causal link 
between insulin resistance and AAA development 
and determine the molecular and cellular 
pathways underlying this association. 
Potential conflict of interest
None declared.
References
 1. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, 
Mansour MA, et al. The Society for Vascular Surgery prac-
tice guidelines on the care of patients with an abdominal 
aortic aneurysm. J Vasc Surg. 2018;67:2-77 e2. https://doi.
org/10.1016/j.jvs.2017.10.044
 2. Golledge J, Muller J, Daugherty A, Norman P. Abdominal 
aortic aneurysm: pathogenesis and implications for ma-
nagement. Arterioscler Thromb Vasc Biol. 2006;26:2605-13. 
https://doi.org/10.1161/01.ATV.0000245819.32762.cb
 3. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pat-
hophysiology and epidemiology of abdominal aortic 
aneurysms. Nat Rev Cardiol. 2011;8:92-102. https://doi.
org/10.1038/nrcardio.2010.180
 4. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham 
M, et al. Management of abdominal aortic aneurysms clini-
cal practice guidelines of the European society for vascular 
surgery. Eur J Vasc Endovasc Surg. 2011;41:S1-S58. https://
doi.org/10.1016/j.ejvs.2010.09.011
 5. Lederle FA. The strange relationship between diabetes and 
abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 
2012;43:254-6. https://doi.org/10.1016/j.ejvs.2011.12.026
 6. Pafili K, Gouni-Berthold I, Papanas N, Mikhailidis DP. Abdo-
minal aortic aneurysms and diabetes mellitus. J Diabetes 
Complications. 2015;29:1330-6. https://doi.org/10.1016/j.
jdiacomp.2015.08.011
 7. Weiss JS, Sumpio BE. Review of prevalence and outco-
me of vascular disease in patients with diabetes melli-
tus. Eur J Vasc Endovasc Surg. 2006;31:143-50. https://doi.
org/10.1016/j.ejvs.2005.08.015
 8. Xiong J, Wu Z, Chen C, Wei Y, Guo W. Association between 
diabetes and prevalence and growth rate of abdominal aor-
tic aneurysms: A meta-analysis. Int J Cardiol. 2016;221:484-
95. https://doi.org/10.1016/j.ijcard.2016.07.016
 9. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pu-
jades-Rodriguez M, Gale CP, et al. Type 2 diabetes and in-
cidence of cardiovascular diseases: a cohort study in 1.9 
million people. Lancet Diabetes Endocrinol. 2015;3:105-13. 
https://doi.org/10.1016/S2213-8587(14)70219-0 
10. Lopez-de-Andrés A, Jiménez-Trujillo I, Jiménez-García R, 
Hernández-Barrera V, de Miguel-Yanes JM, Méndez-Bailón 
M, et al. National trends in incidence and outcomes of ab-
dominal aortic aneurysm among elderly type 2 diabetic 
Biochem Med (Zagreb) 2018;28(3):030702  https://doi.org/10.11613/BM.2018.030702 
8
Lareyre F. et al. Insulin resistance and abdominal aortic aneurysm
and non-diabetic patients in Spain (2003-2012). Cardiovasc 
Diabetol. 2015;14:48. https://doi.org/10.1186/s12933-015-
0216-1
11. De Rango P, Farchioni L, Fiorucci B, Lenti M. Diabetes and 
abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 
2014;47:243-61. https://doi.org/10.1016/j.ejvs.2013.12.007
12. Shantikumar S, Ajjan R, Porter KE, Scott DJ. Diabetes and 
the abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 
2010;39:200-7. https://doi.org/10.1016/j.ejvs.2009.10.014
13. De Rango P, Cao P, Cieri E, Parlani G, Lenti M, Simonte G, Ver-
zini F. Effects of diabetes on small aortic aneurysms under 
surveillance according to a subgroup analysis from a ran-
domized trial. J Vasc Surg. 2012;56:1555-63. https://doi.
org/10.1016/j.jvs.2012.05.078 
14. Le MT, Jamrozik K, Davis TM, Norman PE. Negative asso-
ciation between infra-renal aortic diameter and glycae-
mia: the Health in Men Study. Eur J Vasc  Endovasc Surg. 
2007;33:599-604. https://doi.org/10.1016/j.ejvs.2006.12.017
15. Golledge J, Karan M, Moran CS, Muller J, Clancy P, Dear 
AE, Norman PE. Reduced expansion rate of abdominal 
aortic aneurysms in patients with diabetes may be rela-
ted to aberrant monocyte-matrix interactions. Eur Heart J. 
2008;29:665-72. https://doi.org/10.1093/eurheartj/ehm557
16. Kristensen KL, Dahl M, Rasmussen LM, Lindholt JS. Glycated 
Hemoglobin Is Associated With the Growth Rate of Abdo-
minal Aortic Aneurysms: A Substudy From the VIVA (Viborg 
Vascular) Randomized Screening Trial. Arterioscler Thromb 
Vasc Biol. 2017;37:730-6. https://doi.org/10.1161/ATVBA-
HA.116.308874
17. Takagi H, Umemoto T, ALICE (All-Literature Investigation 
of Cardiovascular Evidence) Group. Diabetes and Abdomi-
nal Aortic Aneurysm Growth. Angiology. 2016;67:513-25. 
https://doi.org/10.1177/0003319715602414
18. Takagi H, Umemoto T, ALICE (All-Literature Investigati-
on of Cardiovascular Evidence) Group. Negative associa-
tion of diabetes with rupture of abdominal aortic ane-
urysm. Diab Vasc Dis Res. 2016;13:341-7. https://doi.
org/10.1177/1479164116651389
19. Lareyre F, Moratal C, Chikande J, Jean-Baptiste E, Hassen-
Khodja R, Neels J, et al. Investigation of Plasma Inflamma-
tory Profile in Diabetic Patients With Abdominal Aortic Ane-
urysm: A Pilot Study. Vasc Endovascular Surg. 2018; [Epub 
ahead of print]
20. Hsu CY, Su YW, Chen YT, Tsai SH, Chang CC, Li SY, et al. Asso-
ciation between use of oral-antidiabetic drugs and the risk 
of aortic aneurysm: a nested case-control analysis. Car-
diovasc Diabetol. 2016;15:125. https://doi.org/10.1186/
s12933-016-0447-9
21. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ash-
ton HA, Hafez H. An analysis of drug modulation of abdomi-
nal aortic aneurysm growth through 25 years of surveillan-
ce. J Vasc Surg. 2010;52:55–61.e2. https://doi.org/10.1016/j.
jvs.2010.02.012
22. Hwang MH, Lee S. Insulin resistance: vascular function 
and exercise. Integr Med Res. 2016;5:198-203. https://doi.
org/10.1016/j.imr.2016.06.001
23. Muniyappa R, Sowers JR. Role of insulin resistance in endo-
thelial dysfunction. Rev Endocr Metab Disord. 2013;14:5-12. 
https://doi.org/10.1007/s11154-012-9229-1
24. Shoelson SE, Lee J, Goldfine AB. Inflammation and insu-
lin resistance. J Clin Invest. 2006;116:1793-801. https://doi.
org/10.1172/JCI29069
25. Martínez-Hervás S, Vinué Á, Núñez L, Andrés-Blasco I, Piqu-
eras L, Real JT, et al. Insulin resistance aggravates atheros-
clerosis by reducing vascular smooth muscle cell survi-
val and increasing CX3CL1/CX3CR1 axis. Cardiovasc Res. 
2014;103:324-36. https://doi.org/10.1093/cvr/cvu115
26. Vassault A, Grafmeyer D, de Graeve J, Cohen R, Beaudonnet 
A, Bienvenu J. Analyses de biologie médicale : spécifications 
et normes d’acceptabilité à l’usage de la validation de tech-
niques. Ann Biol Clin. 1999;57:685-95.
27. Ricós C, Alvarez V, Cava F, García-Lario JV, Hernán-
dez   A, Jiménez CV, et al. Current databases on bi-
ological variation:pros, cons and progress. Scand 
J Clin Lab Invest. 1999;59:491-500. https://doi.
org/10.1080/00365519950185229
28. American Diabetes Association. Diagnosis and classifica-
tion of diabetes mellitus. Diabetes Care. 2014;37:S81-90. 
https://doi.org/10.2337/dc14-S081
29. The Homeostasis Model Assessment Calculator. Available 
at: https://www.dtu.ox.ac.uk/homacalculator/. Accessed 
December 5th 2017.
30. Arapoglou V, Kondi-Pafiti A, Rizos D, Carvounis E, Fran-
gou-Plemenou M, Kotsis T, et al. The influence of diabetes 
on degree of abdominal aortic aneurysm tissue inflamma-
tion. Vasc Endovascular Surg. 2010;44:454-9. https://doi.
org/10.1177/1538574410363748 
31. Astrand H, Ryden-Ahlgren A, Sundkvist G, Sandgren T, Lanne 
T. Reduced aortic wall stress in diabetes mellitus. Eur J Vasc 
Endovasc Surg. 2007;33:592-8. https://doi.org/10.1016/j.
ejvs.2006.11.011
32. Koole D, van Herwaarden JA, Schalkwijk CG, Lafeber F, 
Vink A, Smeets MB, et al. A potential role for glycated cro-
ss-links in abdominal aortic aneurysm disease. J Vasc 
Surg. 2017;65:1493-503.e3. https://doi.org/10.1016/j.
jvs.2016.04.028
33. Zhang F, Kent KC, Yamanouchi D, Zhang Y, Kato K, Tsai S, 
et al. Anti-receptor for advanced glycation end products 
therapies as novel treatment for abdominal aortic aneu-
rysm. Ann Surg. 2009;250:416-23. https://doi.org/10.1097/
SLA.0b013e3181b41a18
34. Preil SA, Kristensen LP, Beck HC, Jensen PS, Nielsen PS, Ste-
iniche T, et al. Quantitative Proteome Analysis Reveals 
Increased Content of Basement Membrane Proteins in Ar-
teries From Patients With Type 2 Diabetes Mellitus and 
Lower Levels Among Metformin Users. Circ Cardiovasc Ge-
net. 2015;8:727-35. https://doi.org/10.1161/CIRCGENE-
TICS.115.001165
35. Taimour S, Zarrouk M, Holst J, Rosengren AH, Groop L, 
Nilsson PM, Gottsäter A. Aortic diameter at age 65 in men 
with newly diagnosed type 2 diabetes. Scand Cardiovasc J. 
2017;51:202-6. https://doi.org/10.1080/14017431.2017.131
9971
https://doi.org/10.11613/BM.2018.030702 Biochem Med (Zagreb) 2018;28(3):030702 
  9
Lareyre F. et al. Insulin resistance and abdominal aortic aneurysm
36. Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, 
Azizi F. Age- and sex-specific reference values for fasting se-
rum insulin levels and insulin resistance/sensitivity indices 
in healthy Iranian adults: Tehran Lipid and Glucose Study. 
Clin Biochem. 2014;47:432-8.  https://doi.org/10.1016/j.clin-
biochem.2014.02.007
37. Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, 
Parise ER. Insulin resistance index (HOMA-IR) in the diffe-
rentiation of patients with non-alcoholic fatty liver disease 
and healthy individuals. Arq Gastroenterol. 2010;47:165-9. 
https://doi.org/10.1590/S0004-28032010000200009
38. Park SE, Park CY, Sweeney G. Biomarkers of insulin sensiti-
vity and insulin resistance: Past, present and future. Crit Rev 
Clin Lab Sci. 2015;52:180-90. https://doi.org/10.3109/10408
363.2015.1023429
39. Sénémaud J, Caligiuri G, Etienne H, Delbosc S, Michel JB, 
Coscas R. Translational Relevance and Recent Advances of 
Animal Models of Abdominal Aortic Aneurysm. Arterioscler 
Thromb Vasc Biol. 2017;37:401-10. https://doi.org/10.1161/
ATVBAHA.116.308534
40. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, 
Mallat Z. Monocytes and macrophages in abdominal aor-
tic aneurysm. Nat Rev Cardiol. 2017;14:457-71. https://doi.
org/10.1038/nrcardio.2017.52
41. Fujimura N, Xiong J, Kettler EB, Xuan H, Glover KJ, Mell MW, 
et al. Metformin treatment status and abdominal aortic 
aneurysm disease progression. J Vasc Surg. 2016;64:46-54.
e8.
42. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, 
et al. Peroxisome proliferator-activated receptor ligands re-
duce aortic dilatation in a mouse model of aortic aneurysm. 
Atherosclerosis. 2010;210:51-6. https://doi.org/10.1016/j.
atherosclerosis.2009.10.027
43. Nansseu JR, Fokom-Domgue J, Noubiap JJ, Balti EV, Sobngwi 
E, Kengne AP. Fructosamine measurement for diabetes 
mellitus diagnosis and monitoring: a systematic review and 
meta-analysis protocol. BMJ Open. 2015;5:e007689. https://
doi.org/10.1136/bmjopen-2015-007689
44. Hjellestad ID, Søfteland E, Nilsen RM, Husebye ES, Jonung T. 
Abdominal aortic aneurysms--glycaemic status and morta-
lity. J Diabetes Complications. 2016;30:438-43. https://doi.
org/10.1016/j.jdiacomp.2015.12.015
